Interestingly, p53 mutant tumors, including lung adenocarcinomas, often display loss of heterozygosity (LOH) (Baker et al. 1990; Mitsudomi et al. 2000; Zienolddiny et al. 2001; Liu et al. 2016), suggesting that wild-type p53 activity may be counterselected even in the presence of the mutant. This evidence concerns the gene TP53 and lung adenocarcinoma.